

Stephen G Swisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3870447/publications.pdf>

Version: 2024-02-01

202
papers

11,480
citations

41258

49
h-index

34900

98
g-index

206
all docs

206
docs citations

206
times ranked

14005
citing authors

#	ARTICLE	IF	CITATIONS
1	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1672-1682.	5.1	865
2	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014, 346, 256-259.	6.0	834
3	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. <i>Lancet Oncology</i> , The, 2014, 15, e42-e50.	5.1	427
4	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021, 39, 346-360.e7.	7.7	422
5	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	15.2	357
6	Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2004, 78, 1152-1160.	0.7	309
7	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 6195-6203.	3.2	292
8	Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 825-832.	0.5	280
9	Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 123, 175-183.	0.4	255
10	2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. <i>Cancer</i> , 2004, 101, 1776-1785.	2.0	255
11	Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancers in the Elderly. <i>JAMA Surgery</i> , 2014, 149, 1244.	2.2	227
12	Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a "No Fly Zone". <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1120-1128.	0.4	225
13	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 423-436.	5.7	218
14	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	0.5	205
15	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 90-95.	0.9	188
16	Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. <i>Clinical Cancer Research</i> , 2003, 9, 93-101.	3.2	166
17	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	7.7	160
18	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.	0.8	158

#	ARTICLE	IF	CITATIONS
19	Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 272-279.	0.7	153
20	Proposed Revision of the Esophageal Cancer Staging System to Accommodate Pathologic Response (pP) Following Preoperative Chemoradiation (CRT). <i>Annals of Surgery</i> , 2005, 241, 810-820.	2.1	141
21	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	5.8	140
22	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
23	Genomic heterogeneity of multiple synchronous lung cancer. <i>Nature Communications</i> , 2016, 7, 13200.	5.8	132
24	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 6278-6289.	3.2	130
25	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
26	A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. <i>Cancer</i> , 2001, 92, 279-286.	2.0	119
27	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survivalThe University of Texas MD Anderson Cancer Center experience. <i>Cancer</i> , 2017, 123, 4106-4113.	2.0	118
28	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 3548-3558.	0.8	114
29	Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 607-613.	0.6	112
30	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	0.5	109
31	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
32	Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. <i>Radiotherapy and Oncology</i> , 2015, 115, 257-263.	0.3	105
33	Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-small-Cell Lung Cancer after Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013, 8, 222-228.	0.5	104
34	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8504-8504.	0.8	101
35	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 2978.	5.8	91
36	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-small Cell Lung Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	88

#	ARTICLE	IF	CITATIONS
37	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. <i>Cell Reports</i> , 2017, 19, 1669-1684.	2.9	82
38	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. <i>Cancer Letters</i> , 2015, 357, 179-185.	3.2	81
39	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	3.2	80
40	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1021-1031.	0.5	79
41	Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. <i>Cancer</i> , 2016, 122, 917-928.	2.0	75
42	A Phase II Study of a Paclitaxel-Based Chemoradiation Regimen With Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1967-1972.	0.4	74
43	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020, 21, 341-348.	1.1	70
44	Long-term outcome of Phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 120-127.	0.4	69
45	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). <i>Cancer Gene Therapy</i> , 2000, 7, 530-536.	2.2	63
46	Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 88-93.	0.9	63
47	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	0.5	62
48	Propensity Score-Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 850-857.	0.4	61
49	Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 375-382.	0.5	58
50	Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. <i>Annals of Thoracic Surgery</i> , 2019, 108, 370-376.	0.7	58
51	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018, 31, 947-955.	2.9	56
52	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. <i>Cancer Research</i> , 2019, 79, 125-132.	0.4	56
53	Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2010, 90, 892-899.	0.7	53
54	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 779-791.	0.5	53

#	ARTICLE	IF	CITATIONS
55	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1597.	3.4	53
56	IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Non-“Small Cell Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2864-2873.	1.9	49
57	Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1064-1071.	0.7	48
58	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	0.5	48
59	Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 689-699.	0.4	47
60	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-“small-cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2019, 20, 43-47.	1.1	45
61	Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1812-1816.	0.7	44
62	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 37-46.e7.	1.1	44
63	<i>STK11</i> /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 1720-1733.	3.2	44
64	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	5.8	42
65	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 601-609.	0.5	40
66	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. <i>Oncotarget</i> , 2017, 8, 21994-22002.	0.8	39
67	Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 274-280.	0.3	38
68	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. <i>Oncologist</i> , 2019, 24, 772-782.	1.9	38
69	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019, 20, 30-36.e3.	1.1	37
70	Multomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020, 21, 271.	3.8	36
71	Clinical update of Ad-p53 gene therapy for lung cancer. <i>Surgical Oncology Clinics of North America</i> , 2002, 11, 521-535.	0.6	35
72	Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. <i>Cancer Research</i> , 2016, 76, 3676-3683.	0.4	35

#	ARTICLE	IF	CITATIONS
73	The Supercharged Microvascular Jejunal Interposition. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2007, 19, 56-65.	0.4	34
74	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 295-309.	4.9	34
75	The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1653-1659.	0.7	34
76	Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1648-1655.	0.4	33
77	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
78	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 341-350.	3.2	31
79	Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. <i>Cancer</i> , 2019, 125, 3738-3748.	2.0	31
80	Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 648-655.	2.9	29
81	Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation. <i>Annals of Cardiothoracic Surgery</i> , 2017, 6, 144-151.	0.6	29
82	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1327-1337.	0.4	29
83	Genetic and immunologic therapies for lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 95-101.	0.8	27
84	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1289-1297.	0.5	27
85	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 418-424.	0.7	26
86	Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. <i>Translational Lung Cancer Research</i> , 2018, 8, 97-106.	1.3	26
87	Cancer Surgery Scheduling During and After the COVID-19 First Wave. <i>Annals of Surgery</i> , 2020, 272, e106-e111.	2.1	26
88	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.	1.6	25
89	p53 Gene therapy for lung cancer. <i>Current Oncology Reports</i> , 2002, 4, 334-340.	1.8	24
90	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 100-108.	0.6	23

#	ARTICLE	IF	CITATIONS
91	Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017, 29, 408-415.	0.4	23
92	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	5.8	23
93	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. <i>Surgery</i> , 2017, 161, 1246-1254.	1.0	22
94	Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2018, 7, 2405-2414.	1.3	22
95	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3525-3536.	3.2	22
96	Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. <i>Annals of Surgery</i> , 2021, 274, 1099-1106.	2.1	22
97	¹⁸ F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1519-1534.	2.0	21
98	Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2528-2535.	1.9	20
99	Predictors of survival after resection of primary sarcomas of the chest wall: A large, single-institution series. <i>Journal of Surgical Oncology</i> , 2018, 118, 518-524.	0.8	20
100	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. <i>Journal of Surgical Oncology</i> , 2019, 120, 729-735.	0.8	20
101	Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. <i>Annals of Thoracic Surgery</i> , 2016, 102, 276-281.	0.7	19
102	Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 960-966.	0.6	19
103	Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1671-1677.	0.7	19
104	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1075-1081.	0.7	18
105	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 45-52.	0.6	18
106	Gastroesophageal junction adenocarcinoma. <i>Current Treatment Options in Oncology</i> , 2000, 1, 387-398.	1.3	17
107	Post-Chemoradiation Surgical Pathology Stage Can Customize the Surveillance Strategy in Patients With Esophageal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1139-1144.	2.3	17
108	Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. <i>Annals of Thoracic Surgery</i> , 2019, 107, 277-284.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 770-777.	0.4	16
110	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. <i>Oncogene</i> , 2020, 39, 801-813.	2.6	16
111	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021, 154, 76-83.	0.9	16
112	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2022, 113, 200-208.	0.7	16
113	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. <i>Nature Communications</i> , 2021, 12, 7081.	5.8	16
114	Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. <i>Annals of Thoracic Surgery</i> , 2019, 107, 936-940.	0.7	15
115	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5477-5486.	3.2	15
116	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. <i>Gastric Cancer</i> , 2020, 23, 904-912.	2.7	15
117	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. <i>JAMA Network Open</i> , 2022, 5, e2215589.	2.8	15
118	Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. <i>Advances in Radiation Oncology</i> , 2017, 2, 316-324.	0.6	14
119	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. <i>Oncotarget</i> , 2018, 7, e1376156.	2.1	14
120	Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2019, 108, 845-851.	0.7	14
121	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1404-1412.e2.	0.4	14
122	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. <i>Chest</i> , 2021, 159, 1256-1264.	0.4	14
123	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. <i>Oncotarget</i> , 2014, 5, 6584-6593.	0.8	14
124	Gene therapy in lung cancer. <i>Current Oncology Reports</i> , 2000, 2, 64-70.	1.8	13
125	Facilitation of Surgical Innovation. <i>Annals of Surgery</i> , 2019, 270, 937-941.	2.1	13
126	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 150-157.	3.2	13

#	ARTICLE	IF	CITATIONS
127	Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. <i>Annals of Thoracic Surgery</i> , 2018, 106, 235-241.	0.7	12
128	Occult stage IIIA-N2 patients have excellent overall survival with initial surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 6670-6676.	0.6	12
129	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 328.	1.8	12
130	Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. <i>Annals of Thoracic Surgery</i> , 2022, 113, 975-983.	0.7	12
131	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	0.8	12
132	Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. <i>Scientific Reports</i> , 2015, 5, 12068.	1.6	11
133	A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 173-179.	2.3	11
134	Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 101, 211-217.	0.7	11
135	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. <i>Cancer</i> , 2018, 124, 1061-1069.	2.0	11
136	HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. <i>Annals of Thoracic Surgery</i> , 2018, 105, 363-370.	0.7	10
137	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. <i>British Journal of Cancer</i> , 2018, 118, 331-337.	2.9	10
138	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. <i>Targeted Oncology</i> , 2018, 13, 99-106.	1.7	10
139	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e294-e301.	1.1	10
140	Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. <i>Journal of Surgical Oncology</i> , 2020, 122, 495-505.	0.8	10
141	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. <i>Oncotarget</i> , 2015, 6, 345-354.	0.8	10
142	SABR vs surgery for NSCLC in the media. <i>Lancet Oncology</i> , The, 2015, 16, e422.	5.1	9
143	Limitations of 18F-2-Deoxy-d-Glucose Positron Emission Tomography in N1 Detection in Patients With Pathologic Stage II-N1 and Implications for Management. <i>Annals of Thoracic Surgery</i> , 2015, 99, 414-420.	0.7	9
144	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 358-366.	0.7	9

#	ARTICLE	IF	CITATIONS
145	Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. <i>Annals of Thoracic Surgery</i> , 2021, 112, 423-429.	0.7	9
146	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9017-9017.	0.8	9
147	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 2461-2473.	3.2	9
148	Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5234-5240.	1.4	8
149	Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1710-1714.	0.7	8
150	Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. <i>Annals of Thoracic Surgery</i> , 2020, 109, 404-411.	0.7	8
151	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, 751-757.	2.1	8
152	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. <i>Annals of Thoracic Surgery</i> , 2022, 114, 2032-2040.	0.7	8
153	Influence of Age on Choice of Therapy and Surgical Outcomes in Patients with Nonsmall Cell Lung Cancer. <i>American Surgeon</i> , 2009, 75, 598-604.	0.4	7
154	Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1821-1828.	0.7	7
155	Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2021, . .	0.7	7
156	RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. <i>Oncotarget</i> , 2015, 6, 11114-11124.	0.8	7
157	Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1499-1503.	0.7	6
158	Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. <i>Journal of Thoracic Disease</i> , 2019, 11, 3391-3398.	0.6	6
159	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. <i>Journal of Thoracic Disease</i> , 2020, 12, 1952-1959.	0.6	6
160	Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 337-343.	0.4	6
161	Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance. <i>Oncotarget</i> , 2016, 7, 38235-38242.	0.8	6
162	Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2635-2645.e15.	0.4	5

#	ARTICLE	IF	CITATIONS
163	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1621-1626.	0.7	5
164	Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 184-190.	0.6	5
165	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1133-1140.	0.7	5
166	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. <i>American Journal of Cancer Research</i> , 2020, 10, 4464-4475.	1.4	5
167	Barriers to surveillance imaging adherence in early-staged lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 6848-6854.	0.6	5
168	Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Annals of Surgical Oncology</i> , 2007, 14, 1305-1311.	0.7	4
169	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. <i>Journal of Thoracic Disease</i> , 2020, 12, 329-337.	0.6	4
170	T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8532-8532.	0.8	4
171	Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model. <i>Surgery</i> , 2022, 171, 504-510.	1.0	4
172	Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2020, 15, 57-65.	0.4	3
173	Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. <i>Journal of Surgical Oncology</i> , 2020, 122, 515-522.	0.8	3
174	Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2185-2191.	0.9	3
175	Impact of Psychiatric Comorbidities on Surgical Outcomes for Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1008-1014.	0.7	3
176	Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8542-8542.	0.8	3
177	Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. <i>Oncotarget</i> , 2017, 8, 79356-79365.	0.8	3
178	Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. <i>Oncotarget</i> , 2017, 8, 102150-102160.	0.8	3
179	Role of neoadjuvant chemoimmunotherapy for resectable NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 497-498.	12.5	3
180	Stage I lung cancer – to operate or to radiate? that is the question. <i>Journal of Thoracic Disease</i> , 2016, 8, 2324-2327.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Oesophageal preservation in locally advanced oesophageal cancer. <i>Lancet Oncology</i> , The, 2018, 19, e430.	5.1	2
182	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020, 146, 303-309.	0.9	2
183	Synchronous Esophageal and Lung Cancers—Is Combined Anatomic Resection Appropriate?. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1354-1360.	0.7	2
184	Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. <i>Journal of Surgical Oncology</i> , 2021, 124, 699-703.	0.8	2
185	Optimizing Discharge After Shorter Hospitalizations: Lessons Learned Through After-Hours Calls with Thoracic Surgical Patients. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2021, 16, 155698452110413.	0.4	2
186	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. <i>Lung Cancer</i> , 2022, 164, 69-75.	0.9	2
187	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. <i>Blood Advances</i> , 2022, 6, 891-901.	2.5	2
188	Brief Report: Surgical Complexity of Pulmonary Resections Performed for Oligometastatic Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100288.	0.6	2
189	Single Chest Drain Practice Reduces Discharge Opioid Prescriptions in Thoracic Surgery. <i>Thoracic and Cardiovascular Surgeon</i> , 2022, 70, 422-429.	0.4	2
190	Influence of lymph node dissection on survival in esophageal cancer. , 1998, 69, 117-117.		1
191	Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. <i>Oncology</i> , 2018, 94, 345-353.	0.9	1
192	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. <i>Journal of Surgical Oncology</i> , 2020, 121, 984-989.	0.8	1
193	Development of Miniature Y Stent for Treatment of Postoperative Bronchial Stenosis. <i>Annals of Thoracic Surgery</i> , 2020, 110, e99-e101.	0.7	1
194	Clinical Significance of FDG-PET/CT Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. <i>Annals of Thoracic Surgery</i> , 2021, , .	0.7	1
195	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14047-e14047.	0.8	1
196	Glutathione reductase () gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. <i>American Journal of Cancer Research</i> , 2019, 9, 1201-1211.	1.4	1
197	The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. <i>Journal of Surgical Research</i> , 2022, 277, 125-130.	0.8	1
198	Consolidative local therapy in oligometastatic patients — Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e62.	5.1	0

#	ARTICLE	IF	CITATIONS
199	Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1111-1117.	0.7	0
200	Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. <i>Annals of Thoracic Surgery</i> , 2021, , .	0.7	0
201	Heterogeneity of stage IIIA leads to difficulty in determining optimal treatment. <i>Journal of Thoracic Disease</i> , 2019, 11, S2043-S2045.	0.6	0
202	Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. <i>Ecological Management and Restoration</i> , 2021, , .	0.2	0